Study #2021-1089
Risk reducing salpingectomy with delayed oophorectomy as an alternative to risk- reducing salpingo-oophorectomy in High Risk-Women to assess the Safety of Prevention ? US cohort study
MD Anderson Study Status
Enrolling
Treatment Agent
Description
This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Ovarian Cancer;Fallopian Tube Cancer
Study phase:
Not applicable
Physician name:
Roni Wilke
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-934-6089
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.